The retina may unlock risk of Alzheimer’s in middle age
February 16th 2022Researchers know that parts of the retina are considered as biomarkers for Alzheimer’s, but the team from Otago’s Dunedin Multidisciplinary Health and Development Research Unit in New Zealand have been investigating the retina’s potential to indicate cognitive change earlier in life.
Read More
AffaMed gets FDA IND clearance for AM712 to treat retinal vascular diseases
February 15th 2022AM712 is a novel bispecific biologic molecule specifically designed for ocular use. In pre-clinical studies, it demonstrated efficacy, ocular pharmacokinetics, and the desired safety profile supporting clinical exploration.
Read More
Unity provides Phase 1 study data for UBX1325
February 14th 2022During a presentation at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wAMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.
Read More
FDA approves generic version of cyclosporine ophthalmic emulsion as dry eye treatment
February 4th 2022The FDA has approved the first generic of cyclosporine ophthalmic emulsion (Restasis; Allergan) 0.05% single-use vials of eye drops to increase tear production in patients with dry eye disease.
Read More
Heidelberg Engineering supporting Glaucoma/Myopia OCT Phenotyping Consortium
February 1st 2022The GMOPC was established in February 2020 at an inaugural meeting in Los Angeles, California, as an investigator-initiated clinical research study, with Heidelberg Engineering as an industry partner.
Read More